---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179446"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:07:16.537814+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# XOMA Royalty Q2 net income $9.2M; acquires Turnstone, HilleVax, LAVA; H1 cash receipts $29.6M

## Summary
- Net income $9.2M (Q2 2025) vs $16.0M (Q2 2024); income & revenue $13.1M vs $11.1M.
- H1 2025 cash receipts $29.6M ($16.0M royalties, $13.6M milestones); Q2 cash receipts $11.7M.
- Completed Turnstone acquisition (Aug 11); HilleVax expected Sept; LAVA expected Q4 2025.
- Deployed $20M for additional mezagitamab royalty; $5M milestone from Rezolute, $3M from Takeda.
- Repurchased 107,500 shares in H1 for $2.4M; paid $2.7M in preferred stock dividends.

## SEC filing metadata
- accession: 0001193125-25-179446
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/0001193125-25-179446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179446
- JSON: https://secwatch.observer/filing/0001193125-25-179446.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.